Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 5/2021

01-09-2021 | Osteoporosis | Original Article

Protective effects of berberine on senile osteoporosis in mice

Authors: Qing-Chang Chen, Yuan-Lin Pu, Jing Bi, Yan Zhang

Published in: Journal of Bone and Mineral Metabolism | Issue 5/2021

Login to get access

Abstract

Introduction

The incidence of osteoporosis is positively correlated with age. Berberine has been reported to treat osteoporosis due to its beneficial actions on bone formation. However, the direct effects of berberine on senile osteoporosis remain unclear. The present study investigated the protective effects of berberine on senile osteoporosis in mice and preliminarily evaluated its potential mechanism.

Materials and methods

20-month-old male C57BL/6 J mice were used as senile osteoporosis mouse model and treated with strontium ranelate (SR) or berberine or solvent control by daily gavage for 2 months. Thereafter, bone mass and microstructure parameters were assessed. Histological staining was performed to identify the osteogenic, adipogenic and osteoclastic activity of bone tissue. Moreover, role of cAMP/PKA/CREB signaling pathway in berberine affecting bone marrow mesenchymal stem cells (BMSCs) differentiation was clarified by enzyme-linked immunosorbent assay and western blot analysis.

Results

The results showed that the SR-treated group displayed a high trabecular bone mass phenotype. For mice administrated with berberine, cancellous bone mass was upregulated in a dose-dependent manner, as indicated by gradually increased bone mass, trabecular bone volume fraction and trabecular number. Furthermore, berberine promotes osteogenic and inhibits adipogenic differentiation of BMSCs via cAMP/PKA/CREB signaling. Also, bone resorption effect becomes more obvious with increasing dose of berberine in vitro.

Conclusion

The present results suggest that berberine exerts potent bone protective effects by promoting bone formation, inhibiting marrow fat accumulation and bone resorption. This effect may be achieved through cAMP/PKA/CREB signaling pathway.
Literature
1.
go back to reference Agidigbi TS, Kim C (2019) Reactive oxygen species in osteoclast differentiation and possible pharmaceutical targets of ROS-mediated osteoclast diseases. Int J Mol Sci 20:3576CrossRef Agidigbi TS, Kim C (2019) Reactive oxygen species in osteoclast differentiation and possible pharmaceutical targets of ROS-mediated osteoclast diseases. Int J Mol Sci 20:3576CrossRef
2.
go back to reference He XF, Zhang L, Zhang CH, Zhao CR, Li H, Zhang LF, Tian GF, Guo MF, Dai Z, Sui FG (2017) Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway. Bosn J Basic Med Sci 17:295–301PubMedPubMedCentral He XF, Zhang L, Zhang CH, Zhao CR, Li H, Zhang LF, Tian GF, Guo MF, Dai Z, Sui FG (2017) Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway. Bosn J Basic Med Sci 17:295–301PubMedPubMedCentral
3.
go back to reference Coughlan T, Dockery F (2014) Osteoporosis and fracture risk in older people. Clin Med 14:187–191CrossRef Coughlan T, Dockery F (2014) Osteoporosis and fracture risk in older people. Clin Med 14:187–191CrossRef
4.
go back to reference Armas LA, Recker RR (2012) Pathophysiology of osteoporosis: new mechanistic insights. Endocrinol Metab Clin North Am 41:475–486CrossRef Armas LA, Recker RR (2012) Pathophysiology of osteoporosis: new mechanistic insights. Endocrinol Metab Clin North Am 41:475–486CrossRef
5.
go back to reference Callaway DA, Jiang JX (2015) Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases. J Bone Miner Metab 33:359–370CrossRef Callaway DA, Jiang JX (2015) Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases. J Bone Miner Metab 33:359–370CrossRef
6.
go back to reference Ruiz-Adame M, Correa M (2020) A systematic review of the indirect and social costs studies in fragility fractures. Osteoporos Int 31:1205–1216CrossRef Ruiz-Adame M, Correa M (2020) A systematic review of the indirect and social costs studies in fragility fractures. Osteoporos Int 31:1205–1216CrossRef
7.
go back to reference Wang K, Feng X, Chai L, Cao S, Qiu F (2017) The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev 49:139–157CrossRef Wang K, Feng X, Chai L, Cao S, Qiu F (2017) The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev 49:139–157CrossRef
8.
go back to reference Delannoy P, Bazot D, Marie PJ (2002) Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism 51:906–911CrossRef Delannoy P, Bazot D, Marie PJ (2002) Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism 51:906–911CrossRef
9.
go back to reference Geoffroy V, Chappard D, Marty C, Libouban H, Ostertag A, Lalande A, de Vernejoul MC (2011) Strontium ranelate decreases the incidence of new caudal vertebral fractures in a growing mouse model with spontaneous fractures by improving bone microarchitecture. Osteoporos Int 22:289–297CrossRef Geoffroy V, Chappard D, Marty C, Libouban H, Ostertag A, Lalande A, de Vernejoul MC (2011) Strontium ranelate decreases the incidence of new caudal vertebral fractures in a growing mouse model with spontaneous fractures by improving bone microarchitecture. Osteoporos Int 22:289–297CrossRef
10.
go back to reference Wong SK, Chin KY, Ima-Nirwana S (2020) Berberine and musculoskeletal disorders: the therapeutic potential and underlying molecular mechanisms. Phytomedicine 73:152892CrossRef Wong SK, Chin KY, Ima-Nirwana S (2020) Berberine and musculoskeletal disorders: the therapeutic potential and underlying molecular mechanisms. Phytomedicine 73:152892CrossRef
11.
go back to reference Pang B, Zhao LH, Zhou Q, Zhao TY, Wang H, Gu CJ, Tong XL (2015) Application of berberine on treating type 2 diabetes mellitus. Int J Endocrinol 201:905749 Pang B, Zhao LH, Zhou Q, Zhao TY, Wang H, Gu CJ, Tong XL (2015) Application of berberine on treating type 2 diabetes mellitus. Int J Endocrinol 201:905749
12.
go back to reference Li Z, Geng YN, Jiang JD, Kong WJ (2014) Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med 2014:289264PubMedPubMedCentral Li Z, Geng YN, Jiang JD, Kong WJ (2014) Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med 2014:289264PubMedPubMedCentral
13.
go back to reference Zou K, Li Z, Zhang Y, Zhang HY, Li B, Zhu WL, Shi JY, Jia Q, Li YM (2017) Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system. Acta Pharmacol Sin 38:157–167CrossRef Zou K, Li Z, Zhang Y, Zhang HY, Li B, Zhu WL, Shi JY, Jia Q, Li YM (2017) Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system. Acta Pharmacol Sin 38:157–167CrossRef
14.
go back to reference Xu D, Yang W, Zhou C, Liu Y, Xu B (2010) Preventive effects of berberine on glucocorticoid-induced osteoporosis in rats. Planta Med 76:1809–1813CrossRef Xu D, Yang W, Zhou C, Liu Y, Xu B (2010) Preventive effects of berberine on glucocorticoid-induced osteoporosis in rats. Planta Med 76:1809–1813CrossRef
15.
go back to reference Li H, Miyahara T, Tezuka Y, Tran QL, Seto H, Kadota S (2003) Effect of berberine on bone mineral density in SAMP6 as a senile osteoporosis model. Biol Pharm Bull 26:110–111CrossRef Li H, Miyahara T, Tezuka Y, Tran QL, Seto H, Kadota S (2003) Effect of berberine on bone mineral density in SAMP6 as a senile osteoporosis model. Biol Pharm Bull 26:110–111CrossRef
16.
go back to reference Zhang J, Tang H, Deng R, Wang N, Zhang Y, Wang Y, Liu Y, Li F, Wang X, Zhou L (2015) Berberine suppresses adipocyte differentiation via decreasing CREB transcriptional activity. PLoS ONE 10:e0125667CrossRef Zhang J, Tang H, Deng R, Wang N, Zhang Y, Wang Y, Liu Y, Li F, Wang X, Zhou L (2015) Berberine suppresses adipocyte differentiation via decreasing CREB transcriptional activity. PLoS ONE 10:e0125667CrossRef
17.
go back to reference Hu JP, Nishishita K, Sakai E, Yoshida H, Kato Y, Tsukuba T, Okamoto K (2008) Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-κB and Akt pathways. Eur J Pharmacol 580:70–79CrossRef Hu JP, Nishishita K, Sakai E, Yoshida H, Kato Y, Tsukuba T, Okamoto K (2008) Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-κB and Akt pathways. Eur J Pharmacol 580:70–79CrossRef
18.
go back to reference Tao K, Xiao D, Weng J, Xiong A, Kang B, Zeng H (2016) Berberine promotes bone marrow-derived mesenchymal stem cells osteogenic differentiation via canonical Wnt/β-catenin signaling pathway. Toxicol Lett 240:68–80CrossRef Tao K, Xiao D, Weng J, Xiong A, Kang B, Zeng H (2016) Berberine promotes bone marrow-derived mesenchymal stem cells osteogenic differentiation via canonical Wnt/β-catenin signaling pathway. Toxicol Lett 240:68–80CrossRef
19.
go back to reference Zhang R, Yang J, Wu J, Xiao L, Miao L, Qi X, Li Y, Sun W (2019) Berberine promotes osteogenic differentiation of mesenchymal stem cells with therapeutic potential in periodontal regeneration. Eur J Pharmacol 851:144–150CrossRef Zhang R, Yang J, Wu J, Xiao L, Miao L, Qi X, Li Y, Sun W (2019) Berberine promotes osteogenic differentiation of mesenchymal stem cells with therapeutic potential in periodontal regeneration. Eur J Pharmacol 851:144–150CrossRef
20.
go back to reference Hu Y, Zhang Y, Ni CY, Chen CY, Rao SS, Yin H, Huang J, Tan YJ, Wang ZX, Cao J, Liu ZZ, Xie PL, Wu B, Luo J, Xie H (2020) Human umbilical cord mesenchymal stromal cells-derived extracellular vesicles exert potent bone protective effects by CLEC11A-mediated regulation of bone metabolism. Theranostics 10:2293–2308CrossRef Hu Y, Zhang Y, Ni CY, Chen CY, Rao SS, Yin H, Huang J, Tan YJ, Wang ZX, Cao J, Liu ZZ, Xie PL, Wu B, Luo J, Xie H (2020) Human umbilical cord mesenchymal stromal cells-derived extracellular vesicles exert potent bone protective effects by CLEC11A-mediated regulation of bone metabolism. Theranostics 10:2293–2308CrossRef
21.
go back to reference Zhu H, Guo ZK, Jiang XX, Li H, Wang XY, Yao HY, Zhang Y, Mao N (2010) A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone. Nat Protoc 5:550–560CrossRef Zhu H, Guo ZK, Jiang XX, Li H, Wang XY, Yao HY, Zhang Y, Mao N (2010) A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone. Nat Protoc 5:550–560CrossRef
22.
go back to reference Siddappa R, Martens A, Doorn J, Leusink A, Olivo C, Licht R, van Rijn L, Gaspar C, Fodde R, Janssen F, van Blitterswijk C, de Boer J (2008) cAMP/PKA pathway activation in human mesenchymal stem cells in vitro results in robust bone formation in vivo. Proc Natl Acad Sci USA 105:7281–7286CrossRef Siddappa R, Martens A, Doorn J, Leusink A, Olivo C, Licht R, van Rijn L, Gaspar C, Fodde R, Janssen F, van Blitterswijk C, de Boer J (2008) cAMP/PKA pathway activation in human mesenchymal stem cells in vitro results in robust bone formation in vivo. Proc Natl Acad Sci USA 105:7281–7286CrossRef
23.
24.
go back to reference Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP (2009) Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int 20:197–207CrossRef Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP (2009) Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int 20:197–207CrossRef
25.
go back to reference Gourlay ML, Overman RA, Ensrud KE (2015) Bone density screening and Re-screening in postmenopausal women and older men. Curr Osteoporos Rep 13:390–398CrossRef Gourlay ML, Overman RA, Ensrud KE (2015) Bone density screening and Re-screening in postmenopausal women and older men. Curr Osteoporos Rep 13:390–398CrossRef
26.
go back to reference Komori T (2015) Animal models for osteoporosis. Eur J Pharmacol 759:287–294CrossRef Komori T (2015) Animal models for osteoporosis. Eur J Pharmacol 759:287–294CrossRef
27.
go back to reference Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ, McDaniel L, Amin S, Rouleau PA, Khosla S (2008) A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res 23:205–214CrossRef Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ, McDaniel L, Amin S, Rouleau PA, Khosla S (2008) A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res 23:205–214CrossRef
28.
go back to reference Jia X, Jia L, Mo L, Yuan S, Zheng X, He J, Chen V, Guo Q, Zheng L, Yuan Q, Xu X, Zhou X (2019) Berberine ameliorates periodontal bone loss by regulating gut microbiota. J Dent Res 98:107–116CrossRef Jia X, Jia L, Mo L, Yuan S, Zheng X, He J, Chen V, Guo Q, Zheng L, Yuan Q, Xu X, Zhou X (2019) Berberine ameliorates periodontal bone loss by regulating gut microbiota. J Dent Res 98:107–116CrossRef
29.
go back to reference Chen B, Lin T, Yang X, Li Y, Xie D, Cui H (2016) Intermittent parathyroid hormone (1–34) application regulates cAMP-response element binding protein activity to promote the proliferation and osteogenic differentiation of bone mesenchymal stromal cells, via the cAMP/PKA signaling pathway. Exp Ther Med 11:2399–2406CrossRef Chen B, Lin T, Yang X, Li Y, Xie D, Cui H (2016) Intermittent parathyroid hormone (1–34) application regulates cAMP-response element binding protein activity to promote the proliferation and osteogenic differentiation of bone mesenchymal stromal cells, via the cAMP/PKA signaling pathway. Exp Ther Med 11:2399–2406CrossRef
30.
go back to reference Yang DC, Tsay HJ, Lin SY, Chiou SH, Li MJ, Chang TJ, Hung SC (2008) cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/OPG mRNA expression in mesenchymal stem cells by suppressing leptin. PLoS ONE 3:e1540CrossRef Yang DC, Tsay HJ, Lin SY, Chiou SH, Li MJ, Chang TJ, Hung SC (2008) cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/OPG mRNA expression in mesenchymal stem cells by suppressing leptin. PLoS ONE 3:e1540CrossRef
31.
go back to reference Li CJ, Cheng P, Liang MK, Chen YS, Lu Q, Wang JY, Xia ZY, Zhou HD, Cao X, Xie H, Liao EY, Luo XH (2015) MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation. J Clin Invest 125:1509–1522CrossRef Li CJ, Cheng P, Liang MK, Chen YS, Lu Q, Wang JY, Xia ZY, Zhou HD, Cao X, Xie H, Liao EY, Luo XH (2015) MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation. J Clin Invest 125:1509–1522CrossRef
Metadata
Title
Protective effects of berberine on senile osteoporosis in mice
Authors
Qing-Chang Chen
Yuan-Lin Pu
Jing Bi
Yan Zhang
Publication date
01-09-2021
Publisher
Springer Singapore
Published in
Journal of Bone and Mineral Metabolism / Issue 5/2021
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-021-01225-2

Other articles of this Issue 5/2021

Journal of Bone and Mineral Metabolism 5/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.